Quinidine gluconate Rx
Generic Name and Formulations:
Quinidine gluconate 324mg; ext-rel tabs.
Various generic manufacturers
Indications for Quinidine gluconate:
Atrial and ventricular arrhythmias (see literature).
Take with fluid and in an upright position. Individualize. Prevention of premature atrial, nodal and ventricular contractions: 324–648mg every 8–12 hrs. Maintenance of sinus rhythm following cardioversion: 648mg every 12 hrs or 486–648mg every 8 hrs.
Complete AV or bundle branch block or other severe intraventricular conduction defects. Myasthenia gravis. Digitalis intoxication. Aberrant impulses, abnormal rhythms due to escape mechanisms.
Atrial flutter; digitalize first. Incomplete AV block. Heart failure. Marginally compensated cardiovascular disease. Hypotension. Renal and hepatic dysfunction. Monitor blood, liver and kidney function in long-term use. Monitor ECG and serum levels if dose is over 2.5g/day. Pregnancy (Cat.C). Nursing mothers.
Class I antiarrhythmic.
Quinidine toxicity increased by amiodarone, cimetidine, ranitidine, diuretics, carbonic anhydrase inhibitors, sodium bicarbonate, verapamil, diltiazem. Potentiates anticoagulants, anticholinergics, neuromuscular blocking agents, phenothiazines, reserpine, timolol. Increases digitalis serum levels. Quinidine levels decreased by barbiturates, hydantoins, rifampin, nifedipine.
Nausea, vomiting, abdominal pain, diarrhea, new or exacerbated arrhythmias, heart block, syncope, cinchonism, headache, blood dyscrasias, hypotension, flushing, allergic reactions, impaired hearing and vision, hepatic dysfunction.
Formerly known under the brand names Duraquin, Quinact, Quinaglute.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds